) recently announced a deal with
) for the promotion of different formulations of Glucophage
(metformin hydrochloride) in China. Glucophage is used for the
treatment of type II diabetes particularly in overweight patients
when diet and exercise alone have failed.
As per the agreement, Merck KGaA and Bristol-Myers will
co-promote the drug in China and share profits.
We are positive on Merck KGaA's decision to collaborate with
Bristol-Myers. The two companies will use their strengths to
expand the geographical reach of Glucophage IR. Both companies
have a long history in the treatment of diabetes. Bristol-Myers
Squibb-SASS has been marketing the drug in China since 1999. This
collaboration will help the drug reach more patients in urban and
rural areas for the treatment of type II diabetes.
As per information provided by the International Diabetes
Federation (IDF), diabetes is a major public health problem in
China, affecting more than 90 million people. China ranks highest
in the number of people suffering from this disease.
Within a short time, Bristol-Myers and Merck KGaA intend to
launch Glucophage XR in China.
This is the second collaboration to be announced by Merck KGaA
this week. The company recently announced a strategic deal with
Nordic Bioscience Clinical Development A/S for its pipeline
candidate, sprifermin (recombinant human FGF-18). Sprifermin is
being developed for osteoarthritis (OA) of the knee.
Merck KGaA carries a Zacks Rank #3 (Hold). Currently,
Lannett Company, Inc.
WuXi Pharma Tech (Cayman) Inc.
) look more attractive with a Zacks Rank #1 (Strong Buy).
BRISTOL-MYERS (BMY): Free Stock Analysis
LANNETT INC (LCI): Free Stock Analysis Report
MERCK KGAA (MKGAF): Get Free Report
WUXI PHARMATECH (WX): Free Stock Analysis
To read this article on Zacks.com click here.